drugset / Trial / NCT04675983
A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the efficacy and safety of sintilimab plus ramucirumab compared to stand of care first-line chemotherapy in participants with advanced gastric or esophagogastric adenocarcinoma.
Timeline
- Start
- 2021-03-10
- Primary completion
- 2023-02-12
- Completion
- 2023-02-12
Outcome
Outcome not reported
Stopped (Business): “Due to the company's development strategy adjustment, Innovent Biologics has decided not to continue this study after consultation with investigators”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | — | Oral |
| Comparator | Cisplatin | Other / unclassified | — | Intravenous |
| Comparator | Oxaliplatin | Small molecule | — | Intravenous |
| Subject | Ramucirumab | Monoclonal antibody | — | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | — | Intravenous |
| Comparator | fluorouracil | Small molecule | — | Intravenous |